Clinical guidelines updated for evaluation, management, treatment of chronic kidney disease
In a 2024 clinical practice guideline issued by the Kidney Disease: Improving Global Outcomes (KDIGO) organization, a ...
HealthDay on MSN20h
Clinical Guidelines Updated for Evaluation, Management, Treatment of CKD
In a 2024 clinical practice guideline issued by the Kidney Disease: Improving Global Outcomes (KDIGO) organization ...
Medscape5d
Major Changes Highlighted in New CKD Management Guidelines
Use of cystatin C for chronic kidney disease evaluation and sodium–glucose cotransporter-2 inhibitors as first-line therapy ...
MedPage Today on MSN10d
Updated CKD Guidelines Promote Cystatin C, Risk Equations, and SGLT2 Inhibitors
Use of cystatin C and SGLT2 inhibitors were highlighted in the Kidney Disease: Improving Global Outcomes (KDIGO) organization ...
Medical Dialogues8d
Updated chronic kidney disease management guidelines recommend SGLT2 inhibitors regardless of diabetes or kidney disease type
Improving Global Outcomes (KDIGO) organization updated its existing clinical practice guideline in 2024 on evaluation and ...
The American Journal of Managed Care9d
New Guideline Updates to Slow CKD Progression and Reduce Cardiovascular Risk
Improving Global Outcomes organization's updates to its 2024 guidelines expand SGLT2 inhibitor use and refine chronic kidney ...
Physician's Weekly6d
Addressing Risk Factors That Drive CKD Risk in Lupus Nephritis
Research shows multiple factors drive CKD risk in lupus nephritis, including nephritic flares, baseline hypertension, renal ...
BioPorto A/S: BioPorto announces guidance for 2025 and aspirations for 2026 towards 2029
Announcement no. 05BioPorto announces guidance for 2025 and aspirations for 2026 towards 2029 Copenhagen, Denmark, March 19, 2025, (GLOBE NEWSWIRE) - BioPorto A/S (BioPorto or Company) ...
BioPorto announces guidance for 2025 and aspirations for 2026 towards 2029
Announcement no. 05 BioPorto announces guidance for 2025 and aspirations for 2026 towards 2029 Copenhagen, Denmark, March 19, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), ...